Skip to main content
Welcome to
Sanofi
About us
About us
U.S. LEADERSHIP
Our Stories
Corporate Compliance
Corporate Compliance
California Compliance Law
Shannon Kelley
California Compliance Law - Sanofi Pasteur
Compliance Program for Sanofi Pasteur
Committed to Transparency
Sanofi Websites in the U.S.
Your Health
Your Health
Vaccines
Science & Innovation
Science & Innovation
Clinical Trials
INVESTIGATOR SPONSORED STUDIES (ISS)
Products & Resources
Products & Resources
Prescription Products
Vaccines Products
Vaccines Products
Yellow Fever Vaccine Information
Generics
Consumer Health (OTC) Products
U.S. Patents
Patient Support Services
Resources for Healthcare Providers
Colorado Disclosure
Vermont Disclosure
Our Responsibility
Our Responsibility
Corporate Social Responsibility
Access to Healthcare
Patient Advocacy at Sanofi in the U.S.
Patient Advocacy at Sanofi in the U.S.
Health Equity at Sanofi in the U.S.
2023 Health Equity Accelerator Awards: Application Guidelines
2022 Health Equity Accelerator Award Winners
Health Equity Accelerator Awards Aim to Expand Solutions for Bigger Impact
Patient Centered Healthcare Value Assessment
Diversity, Equity & Inclusion
Diversity, Equity & Inclusion
A Million Conversations: Addressing Disparities in Healthcare
Diversity in Clinical Trials
Employee Resource Groups
Supplier Diversity
Contributions and Giving
Contributions and Giving
TORCH Awards
Sponsorships
Philanthropic Donations
Healthcare Contributions
Independent Medical Education (IME/CME) Grants
Fellowships
Rare Genetic Disease Fellowships
Patient Assistance Foundations
Pricing Principles
Pricing Principles
2023 Pricing Principles Report
Clear Rationale for Pricing
Limited U.S. Price Increases
Continued Transparency in the U.S.
Prioritizing Patient Affordability
Healthy Planet
Careers
Careers
Benefits
Diversity
Postdoctoral Careers
Physician Careers
Students
Veterans
Investors
Media
Toggle navigation
Home
Press Releases
Subscribe
Social Media
Media Contacts
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Sep 26, 2023
Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for Priority Review
Sep 13, 2023
Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
Photos
4
Sep 12, 2023
ALTUVIIIO® supplemental biologics license application based on positive final results from Phase 3 XTEND-Kids study accepted by FDA
First-in-class ALTUVIIIO offers clinically proven highly effective bleed protection with once-weekly dosing for children with hemophilia A
Aug 24, 2023
Beyfortus™ (nirsevimab-alip) recommended for routine use to protect infants against RSV disease in CDC Morbidity and Mortality Weekly Report
The recommendation helps to ensure all infants have the opportunity to be protected from RSV disease ahead of the next winter virus season
Aug 3, 2023
U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jul 25, 2023
Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
Jul 17, 2023
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jun 25, 2023
ALTUVIIIO™ late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
Jun 8, 2023
FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
Jun 2, 2023
New data from Sanofi’s diverse, differentiated oncology pipeline and portfolio to be presented at ASCO 2023
May 21, 2023
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
May 18, 2023
Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
May 5, 2023
New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline
17 abstracts showcase new data for Dupixent, itepekimab and anti-IL-13/TSLP NANOBODY® molecule in COPD and asthma
May 1, 2023
Sanofi Canada et Diabetes Care Community annoncent une collaboration pour soutenir le parcours de bien-être émotionnel des Canadiens et Canadiennes vivant avec le diabète
Apr 27, 2023
Sanofi completes acquisition of Provention Bio, Inc.
Apr 4, 2023
Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines
Mar 23, 2023
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo
Mar 18, 2023
Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks
Mar 13, 2023
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
Mar 7, 2023
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Mar 3, 2023
Provention Bio Announces the Grant of Inducement Awards
Mar 2, 2023
Sanofi launches R&D Consortium of industry and patient advocacy groups to accelerate medicines development
Feb 28, 2023
Kevzara® (sarilumab) approved by FDA as first and only biologic indicated for patients with polymyalgia rheumatica
Feb 24, 2023
New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa-ngpt) as potential new standard of care for all people living with late-onset Pompe disease
Feb 23, 2023
FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
Feb 23, 2023
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Feb 13, 2023
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US
Feb 8, 2023
Provention Bio to Present at the SVB Securities Global Biopharma Conference
Feb 3, 2023
Provention Bio Announces the Grant of Inducement Awards
Photos
1
Feb 2, 2023
Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®
Jan 25, 2023
NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
Jan 25, 2023
FDA approves expanded label of Enjaymo® (sutimlimab-jome) to include long-term safety and efficacy for people with cold agglutinin disease
Jan 18, 2023
Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
Jan 17, 2023
FDA approves Adacel® for immunization during pregnancy to help protect young infants against pertussis
Jan 6, 2023
Provention Bio Announces the Grant of Inducement Awards
Jan 5, 2023
Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors
Dec 21, 2022
Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo
Dec 2, 2022
Provention Bio Announces the Grant of Inducement Awards
Dec 2, 2022
Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022
Four Sarclisa® (isatuximab-irfc) oral presentations and 11 posters featuring cutting-edge investigational and marketed therapies to be presented
Nov 30, 2022
Sanofi to present new clinical data reinforcing novel therapies across rare blood disorders at ASH 2022
Nov 17, 2022
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
Nov 4, 2022
Provention Bio Announces the Grant of Inducement Awards
Nov 3, 2022
Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 13, 2022
Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022
Oct 7, 2022
Provention Bio Announces the Grant of Inducement Awards
Oct 6, 2022
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Oct 6, 2022
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
Sep 28, 2022
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
Sep 19, 2022
Provention Bio Announces Senior Leadership Addition
Sep 8, 2022
Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
23
»
Print
Email page
RSS
